WO2023052543 - DETECTION OF BLADDER CANCER IN MALES
National phase entry:
Publication Number
WO/2023/052543
Publication Date
06.04.2023
International Application No.
PCT/EP2022/077186
International Filing Date
29.09.2022
Title **
[English]
DETECTION OF BLADDER CANCER IN MALES
[French]
DÉTECTION DU CANCER DE LA VESSIE CHEZ LES HOMMES
Applicants **
RANDOX LABORATORIES LTD
Inventors
FITZGERALD, Stephen Peter
RUDDOCK, Mark
LAMONT, John
Priority Data
2114088.4
01.10.2021
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2047 | |
| EPO | Filing, Examination, Granting | 8216 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,229
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Haematuria is a considerable burden within primary and secondary care; too many haematuria patients are referred to secondary care for invasive and expensive investigations that could be managed in primary care. The current invention has identified biomarker combinations with prolactin and/or LASP-1 with utility for the diagnosis of bladder cancer in males. Using gender specific biomarker algorithms in combination with clinical risks that are associated with bladder cancer, would allow clinicians to better manage haematuria patients in primary care setting.[French]
L'hématurie représente un fardeau considérable dans les soins primaires et secondaires; trop de patients souffrant d'hématurie sont envoyés en soins secondaires pour des recherches invasives et onéreuses qui pourraient être gérées lors de soins primaires. La présente invention a permis d'identifier des combinaisons de biomarqueurs avec la prolactine et/ou LASP-1 qui sont utiles pour le diagnostic du cancer de la vessie chez les hommes. L'utilisation d'algorithmes de biomarqueurs spécifiques au sexe en combinaison avec des risques cliniques qui sont associés au cancer de la vessie, permettrait aux cliniciens de mieux gérer les patients souffrant d'hématurie dans le cadre de soins primaires.